For research use only. Not for therapeutic Use.
PKT-276(CAT: I030144) is an oral bioavailable, selective inhibitor of nuclear export (SINE) and a potent CRM1 antagonist. By irreversibly binding to CRM1, a key protein involved in the export of cargo proteins from the nucleus, PKT-276 disrupts the normal cellular trafficking of several important regulatory proteins. This inhibition leads to the accumulation of tumor suppressor proteins in the nucleus, triggering cell cycle arrest and apoptosis in cancer cells. PKT-276 is being investigated in Cancer Disease Research for its potential to enhance the efficacy of chemotherapy and overcome resistance mechanisms, making it a promising therapeutic agent in cancer treatment.
| CAS Number | 1421919-75-6 |
| Synonyms | (Z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-1-(3,3-difluoroazetidin-1-yl)prop-2-en-1-one |
| Molecular Formula | C16H10F8N4O |
| Purity | ≥95% |
| IUPAC Name | (Z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-1-(3,3-difluoroazetidin-1-yl)prop-2-en-1-one |
| InChI | InChI=1S/C16H10F8N4O/c17-14(18)6-27(7-14)12(29)1-2-28-8-25-13(26-28)9-3-10(15(19,20)21)5-11(4-9)16(22,23)24/h1-5,8H,6-7H2/b2-1- |
| InChIKey | JCHAWRDHMUSLMM-UPHRSURJSA-N |
| SMILES | C1C(CN1C(=O)C=CN2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)(F)F |
